These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36699070)

  • 1. Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis.
    Zhang H; He Y; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Alffenaar JW; Hu Y
    Front Pharmacol; 2022; 13():1032674. PubMed ID: 36699070
    [No Abstract]   [Full Text] [Related]  

  • 2. Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients.
    Shao G; Bao Z; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Alffenaar JW; Hu Y
    Front Pharmacol; 2023; 14():1022090. PubMed ID: 37050904
    [No Abstract]   [Full Text] [Related]  

  • 3. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
    Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
    Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
    Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
    Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India.
    Resendiz-Galvan JE; Arora PR; Abdelwahab MT; Udwadia ZF; Rodrigues C; Gupta A; Denti P; Ashavaid TF; Tornheim JA
    Front Pharmacol; 2022; 13():1081123. PubMed ID: 36686664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis.
    Alghamdi WA; Al-Shaer MH; An G; Alsultan A; Kipiani M; Barbakadze K; Mikiashvili L; Ashkin D; Griffith DE; Cegielski JP; Kempker RR; Peloquin CA
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32778547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China.
    Zheng X; Davies Forsman L; Bao Z; Xie Y; Ning Z; Schön T; Bruchfeld J; Xu B; Alffenaar JW; Hu Y
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34737224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant
    Singh S; Gumbo T; Boorgula GD; Thomas TA; Philley JV; Srivastava S
    Antimicrob Agents Chemother; 2024 Feb; 68(2):e0108023. PubMed ID: 38131673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
    Heysell SK; Mpagama SG; Ogarkov OB; Conaway M; Ahmed S; Zhdanova S; Pholwat S; Alshaer MH; Chongolo AM; Mujaga B; Sariko M; Saba S; Rahman SMM; Uddin MKM; Suzdalnitsky A; Moiseeva E; Zorkaltseva E; Koshcheyev M; Vitko S; Mmbaga BT; Kibiki GS; Pasipanodya JG; Peloquin CA; Banu S; Houpt ER
    Clin Infect Dis; 2023 Feb; 76(3):497-505. PubMed ID: 35731948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis.
    Dong S; Shao G; Davies Forsman L; Wang S; Wang S; Cao J; Bao Z; Bruchfeld J; Alffenaar JC; Liu J; Hu Y; Wu M
    Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38276514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.
    Wasserman S; Denti P; Brust JCM; Abdelwahab M; Hlungulu S; Wiesner L; Norman J; Sirgel FA; Warren RM; Esmail A; Dheda K; Gandhi NR; Meintjes G; Maartens G
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis.
    Graciaa DS; Kipiani M; Magee MJ; Mikiashvili L; Barbakadze K; Bablishvili N; Auld SC; Alghamdi WA; Alshaer MH; Peloquin CA; Avaliani Z; Blumberg HM; Kempker RR
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0040822. PubMed ID: 35916515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
    Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment.
    Wang S; Forsman LD; Xu C; Zhang H; Zhu Y; Shao G; Wang S; Cao J; Xiong H; Niward K; Schön T; Bruchfeld J; Zhu L; Alffenaar JW; Hu Y
    Int J Infect Dis; 2024 Mar; 140():62-69. PubMed ID: 38176643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid for drug-resistant pulmonary tuberculosis.
    Singh B; Cocker D; Ryan H; Sloan DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W; Changpradub D; Hemapanpairoa J; Thunyaharn S
    Infect Chemother; 2021 Sep; 53(3):503-511. PubMed ID: 34405596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections.
    Blackman AL; Jarugula P; Nicolau DP; Chui SH; Joshi M; Heil EL; Gopalakrishnan M
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33257446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linezolid Pharmacokinetics/Pharmacodynamics-Based Optimal Dosing for Multidrug-Resistant Tuberculosis.
    Zhou W; Nie W; Wang Q; Shi W; Yang Y; Li Q; Zhu H; Liu Z; Ding Y; Lu Y; Chu N
    Int J Antimicrob Agents; 2022 Jun; 59(6):106589. PubMed ID: 35405268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.